Clinical Trial Update: Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of Creon IR in pancreatic exocrine insufficiency due to cystic fibrosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• Creon IR (pancrelipase)

Snippet

Sponsor: Abbott | Conditions: Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2016-02-17